Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.
FDA Grants Orphan Drug Designation to Investigational CAR T-Cell Agent in Gastric/GEJ Cancer
The FDA granted Orphan Drug designation to CARsgen Therapeutics for a CAR T-cell treatment it’s developing to treat gastric cancer.
Singapore Clinicians and Scientists Achieve Big Leap in Early Diagnosis of Gastric Cancer Through the Development of Non-Invasive Blood-based Test
Researchers in Singapore have developed a blood test that they believe could be used for early detection of gastric cancer.
UArizona Health Sciences Researchers Find Biomarker that Can Appear Before Stomach Cancer Develops
Researchers at the University of Arizona discovered a biomarker that appears in people before stomach cancer develops and that can be detected... Read More
Oncologie Announces New Data and Analyses from Clinical Programs and Name Change to OncXerna Therapeutics
In a trial combining Keytruda with Oncologie’s investigational drug that targets phosphatidylserine, the response rate was 43% among patients with a low... Read More
Foundation-Funded Lab at MD Anderson Advances Discoveries in Peritoneal Carcinomatosis
About 45% of gastric cancer patients experience peritoneal carcinomatosis (PC), the spread of the cancer to the abdominal lining—a development that’s associated... Read More
Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
CARsgen Therapeutics was granted orphan drug designation by the US FDA for CAR-T Cells for the treatment of gastric and gastroesophageal junction... Read More
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with... Read More
New Grant Awarded to USC for Study of Epigenetic Targets in Gastric Cancer
Some gastric tumors have genetic abnormalities that can be directly targeted with drugs, such as HER2 mutations. But cancer is a complex... Read More